Østergaard, M, Van Vollenhoven, R, Rudin, A
, Hetland, ML, Nordström, D, Nurmohamed, M, Gudbjørnsson, B
, Ørnbjerg, LM, Bøyesen, P, Olsen, I, Lend, K, Hørslev-Petersen, K, Uhlig, T, Sokka-Isler, T, Gröndal, G
, Krabbe, S, Lindqvist, J, Gjertsson, I
, Glinatsi, DE, Kapetanovic, MC, Aga, A-B, Faustini, F, Parmanne, P, Lorenzen, T, Cagnotto, G, Back, J, Hendricks, O, Vedder, D, Rannio, T, Grenholm, E, Lindegaard, HM, Ljosa, M-KA, Brodin, E, Soderbergh, A, Rizk, M, Hermansson, E, Uhrenholt, L, Larsson, P, Just, SA, Bakland, G, Stevens, D, Laurberg, TB, Haavardsholm, EA & Lampa, J 2022, '
Certolizumab-pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: clinical and radiographic 48-weeks results of the investigator-initiated randomized NORDSTAR trial.', EULAR 2022, Copenhagen,
01/06/2022 -
04/06/2022 s. Annals of the Rheumatic Diseases 81 Suppl 1: 38.